193 related articles for article (PubMed ID: 38396800)
1. Developing Folate-Conjugated miR-34a Therapeutic for Prostate Cancer: Challenges and Promises.
Li WJ; Wang Y; Liu X; Wu S; Wang M; Turowski SG; Spernyak JA; Tracz A; Abdelaal AM; Sudarshan K; Puzanov I; Chatta G; Kasinski AL; Tang DG
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396800
[TBL] [Abstract][Full Text] [Related]
2. Developing folate-conjugated miR-34a therapeutic for prostate cancer treatment: Challenges and promises.
Li WJ; Wang Y; Liu X; Wu S; Wang M; Turowski SG; Spernyak JA; Tracz A; Abdelaal AM; Sudarshan K; Puzanov I; Chatta G; Kasinski AL; Tang DG
bioRxiv; 2024 Jan; ():. PubMed ID: 38045265
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-34a, Prostate Cancer Stem Cells, and Therapeutic Development.
Li WJ; Liu X; Dougherty EM; Tang DG
Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139695
[TBL] [Abstract][Full Text] [Related]
4. Chitosan nanoparticle-mediated delivery of miRNA-34a decreases prostate tumor growth in the bone and its expression induces non-canonical autophagy.
Gaur S; Wen Y; Song JH; Parikh NU; Mangala LS; Blessing AM; Ivan C; Wu SY; Varkaris A; Shi Y; Lopez-Berestein G; Frigo DE; Sood AK; Gallick GE
Oncotarget; 2015 Oct; 6(30):29161-77. PubMed ID: 26313360
[TBL] [Abstract][Full Text] [Related]
5. rAAV-based and intraprostatically delivered miR-34a therapeutics for efficient inhibition of prostate cancer progression.
Ai J; Li J; Su Q; Ma H; He R; Wei Q; Li H; Gao G
Gene Ther; 2022 Aug; 29(7-8):418-424. PubMed ID: 34226687
[TBL] [Abstract][Full Text] [Related]
6. Epigallocatechin-3-gallate Enhances the Efficacy of MicroRNA-34a Mimic and MicroRNA-93 Inhibitor Co-transfection in Prostate Cancer Cell Line.
Mokhtari H; Yaghmaei B; Sirati-Sabet M; Jafari N; Mardomi A; Abediankenari S; Mahrooz A
Iran J Allergy Asthma Immunol; 2020 Dec; 19(6):612-623. PubMed ID: 33463130
[TBL] [Abstract][Full Text] [Related]
7. miR-27b and miR-34a enhance docetaxel sensitivity of prostate cancer cells through inhibiting epithelial-to-mesenchymal transition by targeting ZEB1.
Zhang G; Tian X; Li Y; Wang Z; Li X; Zhu C
Biomed Pharmacother; 2018 Jan; 97():736-744. PubMed ID: 29102917
[TBL] [Abstract][Full Text] [Related]
8. LncRNA NEAT1 promotes docetaxel resistance in prostate cancer by regulating ACSL4 via sponging miR-34a-5p and miR-204-5p.
Jiang X; Guo S; Zhang Y; Zhao Y; Li X; Jia Y; Xu Y; Ma B
Cell Signal; 2020 Jan; 65():109422. PubMed ID: 31672604
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-mRNA Regulatory Network Mediates Activation of mTOR and VEGF Signaling in African American Prostate Cancer.
Gujrati H; Ha S; Mohamed A; Wang BD
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328346
[TBL] [Abstract][Full Text] [Related]
10. Bone targeted miRNA delivery system for miR-34a with enhanced anti-tumor efficacy to bone-associated metastatic breast cancer.
Han TY; Hou LS; Li JX; Huan ML; Zhou SY; Zhang BL
Int J Pharm; 2023 Mar; 635():122755. PubMed ID: 36801480
[TBL] [Abstract][Full Text] [Related]
11. Selective targeting of chemically modified miR-34a to prostate cancer using a small molecule ligand and an endosomal escape agent.
Abdelaal AM; Sohal IS; Iyer SG; Sudarshan K; Orellana EA; Ozcan KE; Dos Santos AP; Low PS; Kasinski AL
Mol Ther Nucleic Acids; 2024 Jun; 35(2):102193. PubMed ID: 38745855
[TBL] [Abstract][Full Text] [Related]
12. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44.
Liu C; Kelnar K; Liu B; Chen X; Calhoun-Davis T; Li H; Patrawala L; Yan H; Jeter C; Honorio S; Wiggins JF; Bader AG; Fagin R; Brown D; Tang DG
Nat Med; 2011 Feb; 17(2):211-5. PubMed ID: 21240262
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-34a Attenuates Paclitaxel Resistance in Prostate Cancer Cells via Direct Suppression of JAG1/Notch1 Axis.
Liu X; Luo X; Wu Y; Xia D; Chen W; Fang Z; Deng J; Hao Y; Yang X; Zhang T; Zhou L; Wu Y; Wang Q; Xu J; Hu X; Li L
Cell Physiol Biochem; 2018; 50(1):261-276. PubMed ID: 30282072
[TBL] [Abstract][Full Text] [Related]
14. The RNA-binding protein SART3 promotes miR-34a biogenesis and G
Sherman EJ; Mitchell DC; Garner AL
J Biol Chem; 2019 Nov; 294(46):17188-17196. PubMed ID: 31619517
[TBL] [Abstract][Full Text] [Related]
15. Modulation of miR-34a in curcumin-induced antiproliferation of prostate cancer cells.
Zhu M; Zheng Z; Huang J; Ma X; Huang C; Wu R; Li X; Liang Z; Deng F; Wu J; Geng S; Xie C; Zhong C
J Cell Biochem; 2019 Sep; 120(9):15616-15624. PubMed ID: 31042325
[TBL] [Abstract][Full Text] [Related]
16. Identification and validation of microRNAs that synergize with miR-34a - a basis for combinatorial microRNA therapeutics.
Orellana EA; Li C; Lisevick A; Kasinski AL
Cell Cycle; 2019 Aug; 18(15):1798-1811. PubMed ID: 31258013
[TBL] [Abstract][Full Text] [Related]
17. microRNA-29b inhibits cell growth and promotes sensitivity to oxaliplatin in colon cancer by targeting FOLR1.
Fu Q; Zhang J; Huang G; Zhang Y; Zhao M; Zhang Y; Xie J
Biofactors; 2020 Jan; 46(1):136-145. PubMed ID: 31621972
[TBL] [Abstract][Full Text] [Related]
18. A first-in-class fully modified version of miR-34a with outstanding stability, activity, and anti-tumor efficacy.
Abdelaal AM; Sohal IS; Iyer S; Sudarshan K; Kothandaraman H; Lanman NA; Low PS; Kasinski AL
Oncogene; 2023 Sep; 42(40):2985-2999. PubMed ID: 37666938
[TBL] [Abstract][Full Text] [Related]
19. LEF1 Targeting EMT in Prostate Cancer Invasion Is Regulated by miR-34a.
Liang J; Li Y; Daniels G; Sfanos K; De Marzo A; Wei J; Li X; Chen W; Wang J; Zhong X; Melamed J; Zhao J; Lee P
Mol Cancer Res; 2015 Apr; 13(4):681-8. PubMed ID: 25587085
[TBL] [Abstract][Full Text] [Related]
20. A novel microRNA regulator of prostate cancer epithelial-mesenchymal transition.
Bucay N; Bhagirath D; Sekhon K; Yang T; Fukuhara S; Majid S; Shahryari V; Tabatabai Z; Greene KL; Hashimoto Y; Shiina M; Yamamura S; Tanaka Y; Deng G; Dahiya R; Saini S
Cell Death Differ; 2017 Jul; 24(7):1263-1274. PubMed ID: 28498363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
